HRT vs GLP-1 for menopause weight loss: which is right for you?

Most women gain five to fifteen pounds across the menopause transition, and the weight tends to settle around the midsection in ways it never did before. Two of the most discussed treatments — Hormone Replacement Therapy (HRT) and GLP-1 medications like semaglutide and tirzepatide — work in completely different ways. Understanding the difference matters, because the right choice depends on what is actually driving the weight gain for you.

Why weight gain happens in menopause

Three things shift at once. First, estrogen falls, which changes where the body stores fat — visceral (abdominal) fat increases even when total weight stays the same. Second, lean muscle mass declines by roughly 3–8% per decade after 40, which lowers resting metabolic rate. Third, insulin sensitivity worsens, making the body more prone to storing carbohydrate as fat. Sleep disruption from hot flashes compounds all three by raising cortisol and appetite-driving hormones like ghrelin. Weight gain in midlife is not a willpower problem — it is a hormonal and metabolic one.

What HRT does for weight and body composition

Hormone Replacement Therapy does not directly cause weight loss, and the randomized trials are clear that it does not cause weight gain either. What it does do is shift body composition in a favourable direction: women on estradiol tend to accumulate less visceral fat, preserve more lean muscle, and maintain better insulin sensitivity than untreated peers. HRT also restores sleep, lowers cortisol, and reduces the symptom burden — hot flashes, joint pain, mood — that makes consistent exercise and good eating harder to sustain. The weight effect is indirect but real: HRT removes the headwinds.

What GLP-1 medications do

GLP-1 receptor agonists — semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), and liraglutide — mimic a gut hormone that signals fullness to the brain and slows gastric emptying. The result is a meaningful reduction in appetite and food noise, improved glucose control, and steady weight loss. In clinical trials, semaglutide produces around 15% body-weight loss at one year; tirzepatide produces around 20%. These are pharmacologically driven effects that work regardless of menopausal status, but they are especially powerful for women whose midlife weight gain is being driven by appetite dysregulation and insulin resistance.

Side-by-side: how they compare

• Mechanism — HRT restores estrogen and progesterone; GLP-1 mimics a gut hormone that suppresses appetite
• Primary purpose — HRT treats menopause symptoms; GLP-1 treats obesity and type 2 diabetes
• Weight effect — HRT shifts composition (less visceral fat, more muscle preservation); GLP-1 produces 15–20% body-weight loss
• Symptom relief — HRT resolves hot flashes, sleep, mood, joint pain, vaginal symptoms; GLP-1 does not address these
• Bone protection — HRT actively protects bone density; GLP-1 alone does not, and rapid weight loss can reduce bone mass
• Side effects — HRT: light breast tenderness, spotting in early months; GLP-1: nausea, constipation, reflux, potential muscle loss
• Duration — HRT often continued for years; GLP-1 typically required long-term to maintain weight loss

When HRT is the right starting point

If hot flashes, night sweats, sleep disruption, mood changes, joint pain, or brain fog are present alongside the weight change, HRT should usually come first. Treating the hormonal driver often improves the metabolic environment enough that lifestyle changes — strength training, protein-forward eating, sleep — actually start to work again. Many women find that a few months of HRT plus consistent resistance training is enough to stop the slow drift upward in weight, even without a weight-loss medication.

When a GLP-1 makes sense

A GLP-1 is a strong fit when appetite and food preoccupation are the dominant problem, when BMI is in the obesity range, when insulin resistance or pre-diabetes is documented, or when HRT plus lifestyle has not been enough. GLP-1s are also useful for women who cannot take HRT for medical reasons. The trade-off is that GLP-1 weight loss includes some lean mass loss, which matters more in midlife than at any other life stage — so protein intake and strength training become non-negotiable.

When the combination works best

For many women with significant weight gain and active menopause symptoms, HRT and a GLP-1 together are more effective than either alone. HRT protects bone and muscle during the GLP-1-driven weight loss, preserves the metabolic benefits of estrogen, and treats the symptoms a GLP-1 cannot touch. The GLP-1 provides the appetite control and meaningful weight loss that HRT alone does not deliver. Used together, the two address different pieces of the same problem.

What to do before starting either

• Get a full hormonal and metabolic workup — including FSH, estradiol, A1c, fasting insulin, lipid panel, and thyroid
• Discuss personal and family history of breast cancer, blood clots, and cardiovascular disease with a menopause-trained clinician
• Set up resistance training and adequate protein (1.2–1.6 g per kg per day) before starting a GLP-1 to protect lean mass
• Plan for monitoring — symptom response on HRT at 6–8 weeks; weight, glucose, and side effects on a GLP-1 monthly

The bottom line

HRT and GLP-1s are not competing therapies — they treat different problems that often overlap in midlife. If menopause symptoms are present, start with HRT and reassess weight in three to six months. If appetite and significant excess weight are the central issue, a GLP-1 may be the right tool. For many women, the answer is both, used together under the care of a clinician who understands menopause medicine.

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026